

October 24, 2007



CeaProve(R) Screening Test Meal Set to Make Waves at Diabetes Conference

EDMONTON, ALBERTA -- (MARKET WIRE) -- 10/24/07 -- Ceapro Inc. (TSX VENTURE: CZO) With epidemic increases in the incidence of diabetes - most of which can be prevented - early and regular testing for glucose intolerance is now easier and more pleasant. Ceapro proudly joins the fight against diabetes with CeaProve® screening technology and will have a booth at the Canadian Diabetes Association (CDA)/Canadian Society of Endocrinology and Metabolism (CSEM) Professional Conference, taking place October 24-27 in Vancouver.

Almost a decade in development, the CeaProve® test meal is a more palatable and better tolerated alternative to existing tests for diabetes and pre-diabetes. Consisting of six highly calibrated wafers equivalent to a balanced meal of carbohydrate, protein and fat, two major clinical studies have shown a significant advantage of CeaProve® over the traditional glucose drink. Its oat starch component - derived from Ceapro's proprietary technology - results in a more physiological blood glucose response and, as a result, is reproducible. There are also little to no side effects as there is no major rise and crash of blood glucose. As importantly for those being tested the experience isn't unpleasant, increasing the likelihood of early and regular testing. In addition, CeaProve® does not need to be dispensed in a clinical setting, substantially reducing costs and increasing screening availability and flexibility. Manufacturing of the CeaProve® test kits is underway and commercial rollout is imminent.

The CDA/CSEM Professional Conference is the "must attend" gathering for healthcare professionals and academics working in the fields of endocrinology, diabetes and related health topics. Some 2500 educators, clinicians and scientists will gather to share expertise, ideas and experience, and learn the latest technologies available to deal with this devastating - yet highly preventable - disease. As such it is a prime exposure for CeaProve®. More information will be available at the CeaProve® booth, number 87, at the Vancouver Convention and Exhibition Centre.

About Ceapro Inc.

Ceapro Technology Inc., Ceapro Veterinary Products Inc., Ceapro Active Ingredients Inc. and Ceapro Bioenergy Inc. are wholly owned subsidiaries of Ceapro Inc., which is a Canadian growth-stage biotechnology company. Our primary business activities relate to the development and commercialization of organic products for medical, cosmetic and animal health industries using proprietary technology and natural, renewable resources. We will be applying our technology to become an active participant in the bioenergy sector. We have also introduced health and wellness services employing our CeaProve® diagnostic technology. Ceapro shares trade on the Canadian TSX Venture Exchange under the symbol

CZO. To learn more about Ceapro, visit www.ceapro.com .

The TSX Venture has neither approved nor disapproved of the information contained herein - This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contacts:

Ceapro Inc.

Dr. Mark Redmond

President and CEO

Edmonton: 780-421-4555

Sun International Communications

Nicole Blanchard, B.Sc., B.Comm

Managing Partner

Montreal: 450-973-6600

nicole.blanchard@isuncomm.com